Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07158489 | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC(ORIGIN2) | recruiting | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07169617 | Testing the SurVaxM Vaccine for Lung Cancer Prevention | not yet recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07254650 | Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1(CALMS-1) | not yet recruiting | N/A | 300 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer(RAINFOL-05) | recruiting | Phase 2 | 240 | GenmabINDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07561645 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung(ALPINE 2) | not yet recruiting | Phase 2 | 75 | Technische Universität DresdenOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07698990 | Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC(SOLID) | not yet recruiting | N/A | 1,200 | Shanghai Chest HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786909 | ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer(ERICA-02) | not yet recruiting | N/A | 40 | Centre Leon BerardOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788729 | Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons(PRISMA) | recruiting | N/A | 384 | University of RegensburgOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | recruiting | Phase 1 / Phase 2 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 25, 2026 | clinicaltrials |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | recruiting | Phase 1 | 30 | Christian HinrichsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05948813 | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | recruiting | Phase 2 | 420 | TYK Medicines, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06070870 | Health Education Approach to Lung Screening(HEALS) | recruiting | N/A | 675 | Virginia Commonwealth UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | recruiting | Phase 2 | 96 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT06909201 | Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity | recruiting | — | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06987890 | Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy(Lung-GAP) | recruiting | N/A | 64 | Brigham and Women's HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07250477 | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 56 | University of California, DavisOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07412262 | A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression(NSCLC， YAP) | recruiting | Phase 2 | 32 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | recruiting | Phase 1 | 110 | Moonlight Bio, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07783971 | Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance | recruiting | — | 10 | 958th Army Hospital of the Chinese People's Liberation ArmyOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784959 | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | recruiting | Phase 1 | 54 | Nuvectis Pharma, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04073745 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04310020 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | active not recruiting | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05517811 | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection(TEG) | recruiting | — | 200 | University of Colorado, DenverOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06622174 | Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer(PROMISE) | recruiting | Phase 1 | 32 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) | not yet recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 16 | Aug 24, 2026 | clinicaltrials |
| NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | recruiting | Phase 3 | 442 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07782359 | Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib(NSCLC) | not yet recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 159 | Yale UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT05963867 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | recruiting | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT06739031 | Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors | recruiting | N/A | 126 | Energenx Medical LTD.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07524114 | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)(SHERLOCK) | recruiting | — | 7,000 | University Health Network, TorontoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT07553819 | Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers | not yet recruiting | N/A | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2026source: clinicaltrials